Biopharma Due Diligence

December 10, 2019 Leah Hoffmann

A global biopharma company was evaluating an acquisition whose potential indications ranged from gastrointestinal disorders to ophthalmology. With a key leader out on vacation and the deadline for a non-binding term sheet drawing near, the company’s head of Commercial Business Development turned to Business Talent Group.

In the span of a few days, we delivered a two-person team to help the company extend and finalize its commercial evaluation. A biotech investment specialist customized a model that looked at multiple scenarios and helped size patient populations across different indications. An analyst assessed market access and competitive dynamics. A week later, the team had the figures it needed to make a successful bid; they are now proceeding to the next phase of the acquisition.

About the Author

Leah Hoffmann

Leah Hoffmann is a former journalist who has worked for and The Economist. She is passionate about clear thinking, sharp writing, and strong points of view.

More Content by Leah Hoffmann
Previous Article
Pharmaceutical Target Valuation
Pharmaceutical Target Valuation

The head of M&A at a global pharma company was evaluating an acquisition target based in India. His team ha...

Next Article
Education Due Diligence
Education Due Diligence

A global PE firm was evaluating an acquisition target in the education industry. Concerned about the team’s...

Get our free guide to working with on-demand talent.

Read Now